naa a22 4500 510779581 CHVBK 20180411083242.0 cr unu---uuuuu 180411e20130601xx s 000 0 eng 10.1007/s11892-013-0374-z doi (NATIONALLICENCE)springer-10.1007/s11892-013-0374-z Risk vs Benefit in Diabetes Pharmacotherapy: a Rational Approach to Choosing Pharmacotherapy in Type 2 Diabetes [Elektronische Daten] [Mary Cox, Mark Feinglos] Type 2 diabetes now affects more than 1 in 10 US adults and is a leading cause of morbidity, mortality, and healthcare expense. There are increasing numbers of available pharmacotherapies, with established agents as well as newer drugs developed from hormones in the incretin pathway, among others. New data are accumulating continuously with respect to potential benefits of both long-standing and new agents, as well as risks identified through post-marketing surveillance. Here we review the commonly prescribed pharmacotherapy options with attention to recently published information and provide a rational approach to choice of therapy. Springer Science+Business Media New York, 2013 Type 2 diabetes nationallicence Pharmacotherapy nationallicence Metformin nationallicence Sulfonylurea nationallicence Pioglitazone nationallicence Dipeptidyl peptidase-4 inhibitor nationallicence Glucagon-like-peptide-1 receptor agonist nationallicence Insulin nationallicence Cox Mary Medical Clinic of North Texas, 909 9th Ave, Ste 300, 76104, Fort Worth, TX, USA aut Feinglos Mark Duke University Medical Center, DUMC, Box 3921, 27710, Durham, NC, USA aut Current Diabetes Reports Current Science Inc. 13/3(2013-06-01), 319-328 1534-4827 13:3<319 2013 13 11892 https://doi.org/10.1007/s11892-013-0374-z text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11892-013-0374-z text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Cox Mary Medical Clinic of North Texas, 909 9th Ave, Ste 300, 76104, Fort Worth, TX, USA aut NATIONALLICENCE 700 1- Feinglos Mark Duke University Medical Center, DUMC, Box 3921, 27710, Durham, NC, USA aut NATIONALLICENCE 773 0- Current Diabetes Reports Current Science Inc 13/3(2013-06-01), 319-328 1534-4827 13:3<319 2013 13 11892 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer